Home

Piramal Pharma PE Ratio

Image

Piramal Pharma Ltd

NSE: PPLPHARMA

PE

292.3

Last updated on: Aug 16, 2025

Key Highlights

  • The P/E Ratio of Piramal Pharma Ltd is 292.3 as of 16 Aug 14:56 PM .
  • The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years.
  • The Latest Trading Price of Piramal Pharma Ltd is ₹ 191.75 as of 14 Aug 13:03 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.1 to 39.8 in 5 years. This represents a CAGR of 13.53%.
  • The PE Ratio of Automobile industry is 21.5. The PE Ratio of Finance industry is 19.2. The PE Ratio of IT - Software industry is 26.8. The PE Ratio of Pharmaceuticals industry is 32.7. The PE Ratio of Retail industry is 102.8. The PE Ratio of Textiles industry is 52.5 in 2025.

Historical P/E Ratio of Piramal Pharma Ltd

No data available

Company Fundamentals for Piramal Pharma Ltd

Image

Piramal Pharma Ltd

NSE: PPLPHARMA

Share Price

₹ 191.75

-0.45 (-0.23%)

stock direction

Last updated on: Aug 14, 2025

Market Price of Piramal Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Piramal Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
14 Aug 2025190
13 Aug 2025192.2
12 Aug 2025189.35
11 Aug 2025190
08 Aug 2025189.7
07 Aug 2025191.75
06 Aug 2025186.2
05 Aug 2025193.55
04 Aug 2025195.05
01 Aug 2025190.6

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

che

Weakness

1

che

Opportunity

0

che

Threats

1

che

BlinkX Score for Piramal Pharma Ltd

Asset Value vs Market Value of Piramal Pharma Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Piramal Pharma Ltd25255
Sun Pharmaceutical Industries Ltd394115
Divis Laboratories Ltd162735
Cipla Ltd126313
Torrent Pharmaceuticals Ltd122586
Dr Reddys Laboratories Ltd105095

PE Ratio of Piramal Pharma Ltd Explained

25255

Market cap

98

Earnings

292.3X

PE Ratio

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Piramal Pharma Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Piramal Pharma Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Piramal Pharma Ltd

No data available

* All values are in %

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Piramal Pharma Ltd News Hub

Piramal Pharma receives SBTi validation for its GHG commitment

Piramal Pharma has embarked on its sustainability journey as the Science Based Targets initiative (S

Read more

17 Sept 24

Piramal Pharma to invest $80M to expand its Lexington, Kentucky facility

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization

Read more

30 Sept 24

Piramal Pharma to discuss results

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 January 2025. Powe

Read more

14 Jan 25

Piramal Pharma to declare Quarterly Result

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 23 October 2024. Powe

Read more

15 Oct 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions